Interaction sites of the Epstein–Barr virus Zta transcription factor with the host genome in epithelial cells

References

1. Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T et al. Epstein–Barr virus bzlf1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol 2007; 81:1037–1042 [View Article]
   [Google Scholar]
2. Kalla M, Hammerschmidt W. Human B cells on their route to latent infection – early but transient expression of lytic genes of Epstein–Barr virus. Eur J Cell Biol 2012; 91:65–69 [View Article]
   [Google Scholar]
3. Tierney RJ, Shannon-Lowe CD, Fitzsimmons L, Bell AI, Rowe M. Unexpected patterns of Epstein–Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mrna. Virology 2015; 474:117–130 [View Article]
   [Google Scholar]
4. Mrozek-Gorska P, Buschle A, Pich D, Schwarzmayr T, Fechtner R et al. Epstein–Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc Natl Acad Sci U S A 2019; 116:16046–16055 [View Article]
   [Google Scholar]
5. Hernando H, Shannon-Lowe C, Islam AB, Al-Shahrour F, Rodriguez-Ubreva J et al. The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein–Barr virus-associated proliferative conversion. Genome Biol 2013; 14:R3 [View Article]
   [Google Scholar]
6. Hernando H, Islam AB, Rodriguez-Ubreva J, Forne I, Ciudad L et al. Epstein–Barr virus-mediated transformation of B cells induces global chromatin changes independent to the acquisition of proliferation. Nucleic Acids Res 2014; 42:249–263 [View Article]
   [Google Scholar]
7. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998; 9:395–404 [View Article] [PubMed]
   [Google Scholar]
8. Thorley-Lawson DA, Babcock GJ. A model for persistent infection with Epstein–Barr virus: the stealth virus of human B cells. Life Sci 1999; 65:1433–1453 [View Article] [PubMed]
   [Google Scholar]
9. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G et al. Burkitt’s lymphoma. Lancet 2012; 379:1234–1244 [View Article]
   [Google Scholar]
10. Rowe M, Kelly GL, Bell AI, Rickinson AB. Burkitt’s lymphoma: The rosetta stone deciphering Epstein–Barr virus biology. Semin Cancer Biol 2009; 19:377–388 [View Article]
    [Google Scholar]
11. Vockerodt M, Cader FZ, Shannon-Lowe C, Murray P. Epstein–Barr virus and the origin of Hodgkin lymphoma. Chin J Cancer 2014; 33:591–597 [View Article]
    [Google Scholar]
12. Aozasa K, Zaki MAA. Epidemiology and pathogenesis of nasal Nk/t-cell lymphoma: A mini-review. ScientificWorldJournal 2011; 11:422–428 [View Article]
    [Google Scholar]
13. Rouce RH, Louis CU, Heslop HE. Epstein–Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 2014; 21:476–481 [View Article]
    [Google Scholar]
14. Healy JA, Dave SS. The role of EBV in the pathogenesis of diffuse large B cell lymphoma. Curr Top Microbiol Immunol 2015; 390:315–337 [View Article]
    [Google Scholar]
15. Raab-Traub N. Nasopharyngeal carcinoma: An evolving role for the Epstein–Barr virus. Curr Top Microbiol Immunol 2015; 390:339–363 [View Article]
    [Google Scholar]
16. Tsang CM, Tsao SW. The role of Epstein–Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Virol Sin 2015; 30:107–121 [View Article]
    [Google Scholar]
17. Chen H, Chen H, Castro FA, Hu J-K, Brenner H. Epstein–Barr virus infection and gastric cancer: A systematic review. Medicine (Baltimore) 2015; 94:e792 [View Article]
    [Google Scholar]
18. Kang MS, Kieff E. Epstein–Barr virus latent genes. Exp Mol Med 2015; 47:e131 [View Article]
    [Google Scholar]
19. Minarovits J. Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol 2006; 310:61–80 [View Article] [PubMed]
    [Google Scholar]
20. Bergbauer M, Kalla M, Schmeinck A, Göbel C, Rothbauer U et al. CpG-methylation regulates a class of Epstein–Barr virus promoters. PLoS Pathog 2010; 6:e1001114 [View Article]
    [Google Scholar]
21. Ramasubramanyan S, Osborn K, Flower K, Sinclair AJ. Dynamic chromatin environment of key lytic cycle regulatory regions of the Epstein–Barr virus genome. J Virol 2012; 86:1809–1819 [View Article]
    [Google Scholar]
22. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S et al. Epigenetic histone modification of Epstein–Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol 2012; 86:4752–4761 [View Article]
    [Google Scholar]
23. Niller HH, Wolf H, Minarovits J. Epigenetic dysregulation of the host cell genome in Epstein–Barr virus-associated neoplasia. Semin Cancer Biol 2009; 19:158–164 [View Article] [PubMed]
    [Google Scholar]
24. Woellmer A, Hammerschmidt W. Epstein–Barr virus and host cell methylation: regulation of latency, replication and virus reactivation. Curr Opin Virol 2013; 3:260–265 [View Article]
    [Google Scholar]
25. Kenney SC, Mertz JE. Regulation of the latent-lytic switch in Epstein–Barr virus. Semin Cancer Biol 2014; 26:60–68 [View Article]
    [Google Scholar]
26. Amon W, Farrell PJ. Reactivation of Epstein–Barr virus from latency. Rev Med Virol 2005; 15:149–156 [View Article]
    [Google Scholar]
27. Feederle R, Kost M, Baumann M, Janz A, Drouet E et al. The Epstein–Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo J 2000; 19:3080–3089 [View Article] [PubMed]
    [Google Scholar]
28. Kouzarides T, Packham G, Cook A, Farrell PJ. The BZLF1 protein of EBV has a coiled coil dimerisation domain without a heptad leucine repeat but with homology to the C/EBP leucine zipper. Oncogene 1991; 6:195–204 [PubMed]
    [Google Scholar]
29. Manet E, Rigolet A, Gruffat H, Giot JF, Sergeant A. Domains of the Epstein–Barr virus (EBV) transcription factor-R required for dimerization, DNA-binding and activation. Nucleic Acids Res 1991; 19:2661–2667 [View Article] [PubMed]
    [Google Scholar]
30. Gruffat H, Renner O, Pich D, Hammerschmidt W. Cellular proteins bind to the downstream component of the lytic origin of DNA replication of Epstein–Barr virus. J Virol 1995; 69:1878–1886 [View Article] [PubMed]
    [Google Scholar]
31. Kalla M, Göbel C, Hammerschmidt W. The lytic phase of Epstein–Barr virus requires a viral genome with 5-methylcytosine residues in CpG sites. J Virol 2012; 86:447–458 [View Article]
    [Google Scholar]
32. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol 2005; 79:7338–7348 [View Article] [PubMed]
    [Google Scholar]
33. Bhende PM, Seaman WT, Delecluse HJ, Kenney SC. The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet 2004; 36:1099–1104 [View Article] [PubMed]
    [Google Scholar]
34. Dickerson SJ, Xing Y, Robinson AR, Seaman WT, Gruffat H et al. Methylation-dependent binding of the Epstein–Barr virus BZLF1 protein to viral promoters. PLoS Pathog 2009; 5:e1000356 [View Article] [PubMed]
    [Google Scholar]
35. Heather J, Flower K, Isaac S, Sinclair AJ. The Epstein–Barr virus lytic cycle activator Zta interacts with methylated ZRE in the promoter of host target gene egr1. J Gen Virol 2009; 90:1450–1454 [View Article] [PubMed]
    [Google Scholar]
36. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. AP-1 homolog bzlf1 of Epstein–Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci U S A 2010; 107:850–855 [View Article]
    [Google Scholar]
37. Ramasubramanyan S, Kanhere A, Osborn K, Flower K, Jenner RG et al. Genome-wide analyses of Zta binding to the Epstein–Barr virus genome reveals interactions in both early and late lytic cycles and an epigenetic switch leading to an altered binding profile. J Virol 2012; 86:12494–12502 [View Article]
    [Google Scholar]
38. Flemington E, Speck SH. Epstein–Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. J Virol 1990; 64:4549–4552 [View Article] [PubMed]
    [Google Scholar]
39. Chang Y, Lee HH, Chen YT, Lu J, Wu S-Y et al. Induction of the early growth response 1 gene by Epstein–Barr virus lytic transactivator Zta. J Virol 2006; 80:7748–7755 [View Article] [PubMed]
    [Google Scholar]
40. Hsu M, Wu S-Y, Chang S-S, Su I-J, Tsai CH et al. Epstein–Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. J Virol 2008; 82:3679–3688 [View Article] [PubMed]
    [Google Scholar]
41. Beatty PR, Krams SM, Martinez OM. Involvement of IL-10 in the autonomous growth of EBV-transformed B cell lines. J Immunol 1997; 158:4045–4051 [PubMed]
    [Google Scholar]
42. Tsai SC, Lin SJ, Chen PW, Luo W-Y, Yeh T-H et al. EBV Zta protein induces the expression of interleukin-13, promoting the proliferation of ebv-infected b cells and lymphoblastoid cell lines. Blood 2009; 114:109–118 [View Article] [PubMed]
    [Google Scholar]
43. Ramasubramanyan S, Osborn K, Al-Mohammad R, Naranjo Perez- Fernandez IB, Zuo J et al. Epstein–Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. Nucleic Acids Res 2015; 43:3563–3577 [View Article]
    [Google Scholar]
44. Buschle A, Mrozek-Gorska P, Cernilogar FM, Ettinger A, Pich D et al. Epstein–Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation. Nucleic Acids Res 2021; 49:3217–3241 [View Article]
    [Google Scholar]
45. Hui KF, Ho DN, Tsang CM, Middeldorp JM, Tsao GSW et al. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. Int J Cancer 2012; 131:1930–1940 [View Article]
    [Google Scholar]
46. Honey S, Schneider BL, Schieltz DM, Yates JR, Futcher B. A novel multiple affinity purification tag and its use in identification of proteins associated with a cyclin-CDK complex. Nucleic Acids Res 2001; 29:E24 [View Article] [PubMed]
    [Google Scholar]
47. Young LS, Lau R, Rowe M, Niedobitek G, Packham G et al. Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia. J Virol 1991; 65:2868–2874 [View Article] [PubMed]
    [Google Scholar]
48. Bark-Jones SJ, Webb HM, West MJ. EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymerase II phosphorylation on serine 5. Oncogene 2006; 25:1775–1785 [View Article] [PubMed]
    [Google Scholar]
49. Gallagher A, Armstrong AA, MacKenzie J, Shield L, Khan G et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin’s disease. Int J Cancer 1999; 84:442–448 [View Article] [PubMed]
    [Google Scholar]
50. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25:1754–1760 [View Article]
    [Google Scholar]
51. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH et al. The human genome browser at UCSC. Genome Res 2002; 12:996–1006 [View Article]
    [Google Scholar]
52. Ramírez F, Dündar F, Diehl S, Grüning BA, Manke T. deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res 2014; 42:W187–91 [View Article]
    [Google Scholar]
53. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010; 28:495–501 [View Article]
    [Google Scholar]
54. Machanick P, Bailey TL. MEME-ChIP: motif analysis of large DNA datasets. Bioinformatics 2011; 27:1696–1697 [View Article]
    [Google Scholar]
55. Lui VWY, Wong EYL, Ho Y, Hong B, Wong SCC et al. STAT3 activation contributes directly to Epstein–Barr virus-mediated invasiveness of nasopharyngeal cancer cells in vitro. Int J Cancer 2009; 125:1884–1893 [View Article]
    [Google Scholar]